

Antiviral Therapeutics

Part I: Technologies & Products

By

Prof. K. K. Jain
MD, FRACS, FFPMM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany, Canada, and the USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 490 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015). Essentials of Personalized Medicine (in Russian, with Prof. K. Sharipov as co-author), 2019) was published by LITERRA Publishing House, Moscow. Currently, he is writing "The Handbook of Alzheimer Disease to be published by Springer in 2022.

November 2021 (originally published in 2007 and continuously updated since then)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

0. Executive Summary	18
1. Introduction to Virology	20
Introduction	20
Evolution of viruses.....	20
Virus databases	20
A practical classification of viruses	20
The human virome.....	22
Viral genomics.....	22
Viruses and human health	22
Endogenous retroviruses.....	23
Endogenous retrovirus-disease link	23
Pathomechanism of viral diseases relevant to therapy	24
Viral entry into host cells	24
Immune response to viruses	25
<i>Intrinsic host defense against retroviruses</i>	25
<i>Interferon-induced B cell deletion in chronic viral infections.....</i>	26
Drosha as an interferon-independent antiviral factor	26
Life cycle of virus as basis for antiviral approaches.....	26
Genetic switch in virus infections	27
Emerging viruses	28
Viral-induced cancer	29
Viral infections of the brain	29
Brain's response to viral infections	29
<i>Viral encephalitis.....</i>	30
Antibody-mediated encephalitis	30
Eastern equine encephalitis	30
Endogenous retrovirus related neurological disorders	31
<i>Amyotrophic lateral sclerosis</i>	31
<i>Dementia</i>	31
<i>Multiple sclerosis.....</i>	31
Combination of antivirals with immunosuppression in viral encephalitis.....	32
Molecular diagnosis of viral diseases	32
Prophylaxis versus therapy.....	33
Economic impact of viral diseases	33
Historical landmarks in the development of antiviral therapies	33
2. Antiviral Approaches	36
Classification	36
Antiviral drug discovery and development.....	36
Antiviral drug targets – viral versus cellular	36
Antivirals based on double-stranded RNA activated caspase oligomerizer.....	38
Antimicrobial peptides	38
Human DDX3 protein as a target for developing broad spectrum antiviral agents	38
Immunological approaches.....	39
Basics of immune regulation in relation to viruses	39
<i>Effect of viruses on the immune system.....</i>	39
<i>Latent viral infections and the immune system</i>	40
Immunomodulating agents	40
<i>Amplification of innate immunity.....</i>	40
<i>Blocking the effects of thromboxane A2 on thromboxane receptor</i>	41
<i>Enhancers of immune system</i>	41
<i>Promoting immune-mediated clearance of a chronic viral infections.....</i>	41
<i>Immunoglobulins</i>	42
<i>Bovine lactoferrin.....</i>	42
<i>Quercetin</i>	43
Monoclonal antibodies	43
<i>Antibody production technologies</i>	44
<i>Bavituximab</i>	44
<i>Treatment of viral infection with radiolabeled MAbs</i>	44
<i>Limitations of MAbs and measures to overcome these</i>	45
Interferon-based approaches.....	45
Cholesterol-25-hydroxylase.....	46
Novel antiviral approaches	46
Phosphatidylethanolamine inhibitors as potential antivirals.....	46
Squalamine	46
Synthetic modified hypericin compounds.....	47

Targeting Toll-like receptors	47
<i>Potential and drawbacks of TLR-ligands in viral diseases</i>	48
Use of CRISPR/Cas9 gene editing in antiviral approaches	48
Targeting RNA viruses	49
Inhibition of viral transport from cytoplasm into the cell nucleus.....	49
Nitric Oxide based antiviral therapeutics	49
Amino acid cognate anticodon binding specificity.....	50
Antisense approaches to viral infections.....	50
Antisense oligonucleotides	50
Limitations of antisense oligonucleotides as antivirals	51
Phosphorodiamidate morpholino oligomers.....	51
Gene therapy for viral infections.....	52
RNAi	52
RNAi screens of viral genomes.....	53
RNAi for treatment of viral infections	53
Promise and pitfalls of RNAi gene therapy	54
Role of proteomics in virology	54
Interaction of proteins with viruses	54
Quantitative temporal viromics	55
Management of rapidly evolving pathogens.....	55
Personalized medicine and viral diseases	55
<i>Genomic epidemiology of viral diseases</i>	56
An integrated approach to viral diseases	57
Current problems and needs in antiviral therapy	57
Immunoinformatic approach to vaccine design for emerging infections	58
Broad-spectrum antiviral agents	58
3. Vaccines for Virus Infections	60
Introduction	60
Types of vaccines.....	61
DNA vaccines	61
Live attenuated virus vaccines	62
Measles-vectored vaccines	62
mRNA vaccines	63
Nanotechnology-based vaccines.....	63
<i>Nanobead adjuvants</i>	63
Recombinant viral vaccines	64
SMART vaccines.....	64
Synthetic peptides as vaccines	65
Virally vectored vaccines.....	65
Virosomes.....	66
Vaccines based on reverse genetics.....	67
Virus-like particles	67
Routine vaccination in children against viral infections	68
Personalized vaccines.....	68
Limitations of vaccines	68
Neurological complications of vaccination	69
Future of antiviral vaccines.....	69
4. Role of Nanotechnology in Developing Antiviral Agents.....	72
Introduction	72
Study of interaction of nanoparticles with viruses.....	72
Exosomes and viral infections	73
Nanoparticle antiviral agents.....	73
Silver nanoparticles.....	73
Fullerenes	73
Nanoparticles mimic RNAi for treatment of viral infections.....	74
Nanoviricides	74
Role of micelles in nanopharmaceuticals	74
Some physicochemical characteristics common to polymeric micelles	75
Structure and function of nanoviricides	75
<i>Mechanism of action of NanoViricides</i>	76
<i>Advantages of NanoViricides</i>	77
5. Delivery of Antivirals	80
Introduction	80
Methods of delivery of antiviral agents	80
Local application of antivirals.....	80
Systemic delivery of protein-polymer antiviral drugs.....	81
Controlled delivery of antivirals.....	81
Targeted delivery of antivirals	81

Delivery of antivirals to the brain across the blood-brain barrier	82
Antiviral vaccine delivery systems	82
Minicell vaccine delivery.....	82
Transnasal delivery of vaccines by Newcastle disease virus as vector	82
Transdermal delivery of vaccines	83
<i>Dissolvable microneedle array for vaccine delivery</i>	83
<i>Electroporation for administering DNA vaccines</i>	83
<i>HIV/AIDS vaccination by transdermal application</i>	85
<i>Microneedles for transdermal delivery of vaccines</i>	85
<i>Needle-free delivery of vaccines.....</i>	85
<i>Transdermal vaccines for influenza.....</i>	86
Use of nanotechnology for improving delivery of antivirals	87
Macrophage-based nanoformulated antiretroviral therapy	88
Improvement of antiviral vaccine delivery by nanotechnology.....	88
<i>Bacterial spores for delivery of vaccines.....</i>	88
<i>Chitosan-derived nanoparticles for vaccine delivery</i>	88
<i>Dendrimer-based intracellular delivery of antibodies.....</i>	89
<i>Gold nanorods for delivery of RNA immune activator molecules</i>	89
<i>Lipid nanoparticles for immunostimulatory RNA delivery</i>	89
<i>Liposomal antiviral vaccine preparations</i>	90
<i>Nanoparticles for DNA vaccines.....</i>	90
<i>Nanospheres for controlled release of viral antigens</i>	90
<i>Proteosomes™ as vaccine delivery vehicles</i>	91
<i>Polymeric micelles for delivery of DNA vaccine</i>	91
<i>"Smart" nanoparticles for delivery of vaccines</i>	91
Nanocoating for local viricidal effect	91
Delivery of gene-based antiviral drugs	92
Limitations of delivery of gene, RNAi and antisense therapies.....	92
Systemic delivery of NanoViricides	93
Concluding remarks on delivery of antiviral agents	93
6. Competitive Assessment of Antiviral Approaches	94
Introduction	94
An ideal antiviral agent.....	94
SWOT analysis	94
Concluding remarks	97
7. Influenza Viruses.....	98
Introduction	98
Clinical features of influenza.....	98
Colds due to rhinovirus	98
Effects of influenza on the respiratory system.....	99
Effect of avian influenza on the nervous system.....	99
Epidemiology	99
Supermap of avian influenza	99
Influenza A	100
Avian influenza affecting humans	100
<i>Human infection with a H7N9 Virus</i>	101
Human influenza versus avian influenza	101
H1N1 influenza	102
Immune system and influenza	103
Immune Epitope Database and Analysis Resources	104
Role of Tpl2 in antiviral host defense mechanisms.....	104
Anti-influenza approaches	105
Pharmaceuticals.....	105
Neuraminidase inhibitors	105
<i>Mechanism of action</i>	105
<i>Tamiflu</i>	106
<i>Zanamivir</i>	106
<i>CS-8958</i>	106
<i>Peramivir</i>	107
<i>Resistance to neuraminidase inhibitors</i>	108
<i>Adverse effects of neuraminidase inhibitors.....</i>	108
<i>Concluding remarks on neuraminidase inhibitors.....</i>	109
Other drugs for influenza	109
<i>Adamantanes</i>	109
<i>Baloxavir marboxil</i>	110
<i>Probenecid</i>	110
Current recommendations for the use of antiviral agents for influenza	110
Vaccines	111

<i>Seasonal influenza vaccines</i>	111
<i>Live attenuated influenza vaccine vs. inactivated vaccine</i>	112
<i>Recombinant influenza vaccine</i>	112
<i>Vaccines for H1N1 influenza</i>	113
<i>Vaccine for H5N1 influenza A</i>	113
<i>Vaccines for H7N9 influenza</i>	114
<i>Current status of influenza vaccines</i>	114
<i>Limitations of current influenza vaccines</i>	115
<i>Needs of influenza vaccines</i>	115
<i>Problems with demand and supply of influenza vaccines</i>	116
<i>Problems with access to virus samples</i>	116
<i>FluVac project for development of pandemic influenza vaccine</i>	116
<i>Influenza vaccines for multiple strains of influenza</i>	117
<i>Quadrivalent influenza vaccine</i>	117
<i>Universal influenza vaccines</i>	117
<i>FLU-v universal vaccine</i>	119
<i>Future of influenza vaccines</i>	119
<i>Application of new technologies for influenza vaccines</i>	120
<i>Adjuvants</i>	121
<i>Cell culture-derived influenza vaccines</i>	121
<i>DNA vaccines for avian influenza</i>	122
<i>Epitope-based vaccines for influenza</i>	122
<i>Gene-based vaccines for influenza</i>	123
<i>Live attenuated vaccines</i>	123
<i>MAbs for passive immunization against avian influenza</i>	123
<i>M2e-based human influenza A vaccine</i>	124
<i>RNA vaccines against influenza A</i>	124
<i>Pre-pandemic split antigen H5N1 vaccine</i>	124
<i>Recombinant-protein based influenza vaccines</i>	125
<i>Synthetic avian influenza vaccine</i>	126
<i>Viral vectors for influenza vaccination</i>	126
<i>Virus-like particles as influenza vaccines</i>	126
<i>RNAi-based approaches</i>	128
<i>Inhibition of influenza virus by siRNAs</i>	128
<i>Limitations of RNAi approach to influenza</i>	129
<i>Challenges and future prospects of siRNAs for influenza</i>	129
<i>Antisense approaches</i>	129
<i>NEUGENE® antisense for inhibition of multiple strains of influenza A</i>	130
<i>Nanoviricides against influenza</i>	130
<i>Other innovative approaches</i>	131
<i>Abatacept</i>	131
<i>Bacteriophage for blocking influenza virus entry</i>	131
<i>Polymeric coatings to inactivate influenza virus</i>	132
<i>Cytotoxic therapy</i>	132
<i>Cyanovirin</i>	132
<i>Fludase</i>	132
<i>Multiferon®</i>	132
<i>Pyrrolidine dithiocarbamate</i>	133
<i>Value of antivirals in preventing spread of influenza after exposure</i>	133
<i>Resistance to influenza therapy and efforts to overcome it</i>	134
<i>FLUCURE project</i>	134
<i>NIAID Centers of Excellence for research on pandemic influenza viruses</i>	134
<i>Research on influenza viruses at Bayer</i>	135
<i>Concluding remarks and future</i>	135
8. AIDS/HIV	138
Introduction	138
Epidemiology	138
Current concepts of pathomechanisms	138
Decoding the structure of an entire HIV genome	139
Genetic basis of resistance against HIV	139
Host-pathogen interactions that regulate HIV-1 replication	139
Pathogenesis of AIDS	140
Visualization of the interaction of HIV-1 proteins with target cells	141
Viral latency in HIV	141
Complications of AIDS	141
HIV in the brain	141
Neurological complications of AIDS	142
AIDS dementia	142
AIDS wasting syndrome	142
Coexistent HIV-1 and HSV-2	143

Coexistent hepatitis virus infections with HIV	143
<i>HIV and HBV</i>	143
<i>HIV and HCV</i>	144
Opportunistic infections in AIDS.....	145
<i>HIV and tuberculosis</i>	145
Current therapies.....	145
Aim of anti-HIV drugs.....	146
Nucleoside reverse transcriptase inhibitors.....	147
Non-nucleoside reverse transcriptase inhibitors	148
<i>Efavirenz</i>	148
<i>Etravirine</i>	148
Protease inhibitors	148
<i>Tipranavir</i>	148
<i>Darunavir</i>	148
Fusion inhibitors	149
<i>Enfuvirtide</i>	149
Combinations of drugs for AIDS	149
<i>Truvada</i>	149
<i>Raltegravir, enfuvirtide, and darunavir</i>	150
<i>Current antiretroviral regimens</i>	150
Impact of antiretroviral treatment on transmission of HIV.....	150
Preexposure prophylaxis against HIV.....	151
Postexposure prophylaxis against HIV	151
Antiretroviral therapy in early asymptomatic HIV infection	152
Limitations of current therapies.....	152
Adverse effects of antiretroviral therapy	152
Drug resistance in AIDS.....	153
Effect of interruption of HIV treatment.....	154
Reservoirs of HIV Infection.....	154
Persistance of low-level viremia in HIV-1 patients on retroviral therapy	155
Reconsideration of abandoned therapies for AIDS.....	155
Therapies in development.....	155
Drugs in development for HIV/AIDS	155
<i>NRTIs in development</i>	156
<i>NNRIs in development</i>	156
Novel protease inhibitors	157
<i>Overcoming HIV-1 resistance to PIs</i>	157
<i>PPL-100</i>	158
Entry inhibitors targeting CCR5 receptor	158
<i>Maraviroc</i>	159
<i>SP-01A</i>	159
<i>MAbs targeting CCR5 receptor</i>	160
<i>PRO 140</i>	160
<i>Ibalizumab</i>	161
Integrase inhibitors	161
<i>Raltegravir (Isentress)</i>	161
<i>Elvitegravir</i>	162
<i>Dolutegravir</i>	162
<i>S/GSK1265744</i>	163
<i>LEDGINS</i>	163
Design of fusion inhibitor peptides against enfuvirtide-resistant HIV-1	163
gp120 attachment inhibitors.....	163
Maturation inhibitors	164
Blocking of pre-integration complex translocation	164
Immune enhancers	164
Pyrimidinediones.....	165
Other innovative antiviral approaches against HIV/AIDS.....	166
A filtration device for HIV-1 as an adjunct to the immune system	166
Anti-HIV therapies based on editing enzymes	166
Anti-HIV activity of drugs that stimulate cholesterol efflux	166
Antiviral hyperactivation-limiting therapeutics	166
ATR kinase as a target for anti-HIV drug discovery.....	167
Drugs from natural sources	167
Enhancing immune response by blockade of PD-1 receptor	167
IL-2 as adjunct to antiretroviral therapy	168
In vitro evaluation of antiviral drug activity	168
Methods for sustaining antiviral activity	168
Microbicidal agents for local application in HIV/AIDS	169
<i>Investigational microbicidals against HIV and their limitations</i>	169
<i>CCR5 receptor blockers</i>	170
<i>PSC-Rantes and recombinant chemokine analogs</i>	170

<i>HIV-1 entry inhibitor griffithsin as a topical microbicide</i>	171
<i>Nanotechnology-based topical microbicides</i>	171
<i>Next generation microbicides for HIV.....</i>	171
<i>Vaginal application of anti-retroviral drugs against HIV.....</i>	172
<i>Nanoviricides for HIV/AIDS</i>	172
Prophylactic measures to prevent HIV infection	172
Selective targeting of ITK to block multiple steps of HIV replication.....	173
T cell receptors from HIV controllers.....	173
Cell therapy for HIV/AIDS	173
hESCs converted to T cells for treatment of HIV infection.....	174
Transplantation of genetically modified hematopoietic cells	174
Transplantation of genetically modified T cells	175
Overlapping Peptide-pulsed Autologous Cells.....	175
Gene therapy strategies in HIV/AIDS	175
Gene editing for HIV-1.....	176
Inhibition of HIV-1 replication by lentiviral vectors	176
VRX496-T (Lexgenleucel-T).....	177
Insertion of protective genes into target cells	177
Use of genes to chemosensitize HIV-1 infected cells.....	177
Autocrine interferon- β production by somatic cell gene therapy	178
Intracellular immunization in HIV	178
<i>Engineered cellular proteins such as soluble CD4s.....</i>	178
<i>Intracellular antibodies</i>	178
<i>Selection of T cell vaccine antigens</i>	179
<i>Glycoprotein 120 as target for neutralizing HIV-1 antibodies</i>	179
<i>Anti-rev single chain antibody fragment.....</i>	179
HIV/AIDS vaccines	179
<i>Cell-based vaccines for HIV.....</i>	180
<i>Delivery of HIV vaccine by an adenoviral vector.....</i>	181
<i>DNA vaccines for HIV/AIDS.....</i>	182
<i>Epitope-based DNA vaccines against HIV</i>	182
<i>Gene transfer for HIV vaccination</i>	183
<i>Recombinant HIV proteins.....</i>	183
<i>Vaccination after discontinuation of antiretroviral treatment.....</i>	183
Innovations in HIV/AIDS vaccine	183
<i>Attenuated rabies virus-based vaccine for HIV.....</i>	183
<i>Dendritic cell-based vaccine for HIV</i>	184
<i>DermaVir</i>	184
<i>Early control of HIV by an effector memory T cell vaccine</i>	185
<i>Immunogens for inducing broadly neutralizing antibodies</i>	185
<i>MVA nef vaccine</i>	185
<i>Peptide-based vaccine for HIV</i>	186
<i>Personalized vaccine for HIV.....</i>	186
<i>RV144 HIV vaccine trial</i>	186
<i>Transdermal nanoparticles for immune enhancement in HIV.....</i>	187
<i>Vaccine to prevent HIV entry at the mucosal level.....</i>	187
Limitations and future of HIV vaccines.....	187
Antisense approaches to AIDS	188
<i>Antisense oligodeoxynucleotides</i>	188
<i>Antisense efforts with PNA constructs</i>	189
<i>RNA decoys.....</i>	189
<i>Ribozymes</i>	190
RNAi applications in HIV/AIDS	190
<i>A multiple shRNA approach for silencing of HIV-1.....</i>	191
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	191
<i>Bispecific siRNA constructs</i>	191
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	191
<i>siRNA-directed inhibition of HIV-1 infection</i>	192
<i>Synergistic effect of snRNA and siRNA</i>	193
<i>Targeting CXCR4 with siRNAs</i>	193
<i>Targeting CCR5 with siRNAs</i>	194
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	194
Companies involved in developing gene therapy for HIV/AIDS	195
Conclusions regarding gene therapy of HIV/AIDS	195
Testing for new anti-HIV therapies.....	196
Personalized approach to management of HIV	196
Differences in response of the body to HIV.....	196
Variations in action of drugs on HIV	197
<i>Drug-resistance in HIV</i>	197
<i>PhenoSense® to test HIV drug resistance</i>	197
<i>Role of biomarkers in management of HIV/AIDS</i>	198

<i>Role of diagnostic testing in management of HIV</i>	198
<i>Prevention of adverse reactions to antiviral drugs</i>	199
<i>Nanoviricides as a personalized approach to HIV.....</i>	199
Concluding remarks and future.....	199
9. Hepatitis Viruses	202
Introduction	202
Hepatitis delta virus infection.....	202
Hepatitis A virus infection.....	202
Hepatitis E virus infection	203
Epidemiology.....	203
Structure of the HEV	203
Treatment of HEV infection	203
<i>Ribavirin</i>	203
<i>Zinc as a potential anti-HEV agent</i>	204
<i>Vaccines for hepatitis E.....</i>	204
Epidemiology of HBV.....	204
Pathogenesis of HBV-induced liver disease.....	205
Current approaches to management of HBV	205
Entecavir	206
Adefovir dipivoxil	206
Telbivudine	206
Pegylated interferon-alpha	207
Limitations of current therapies and needs of HBV	207
Personalized management of HBV	207
Innovations in the management of HBV	208
Tenofovir disoproxil fumarate	208
Hepatitis B immune globulins	208
<i>Nabi-HB.....</i>	208
<i>HepaGam B.....</i>	209
Hepatitis B vaccine composed in a novel nanoemulsion adjuvant	209
Innovative pharmaceuticals for HBV	209
<i>AGX-1009</i>	209
<i>Clevudine.....</i>	210
<i>Helioxanthin analog 8-1.....</i>	210
<i>HepDirect prodrugs.....</i>	210
Monoclonal antibodies for HBV	210
RNAi-based therapy of HBV	211
Personalized treatment of hepatitis B	211
Concluding remarks and future prospects of management of hepatitis B	212
Epidemiology of HCV.....	212
HCV characteristics.....	212
Pathomechanism of HCV infection	213
Mechanism of HCV entry	213
HCV and the immune system	213
Mechanism of HCV replication and response to interferon.....	213
Current approaches to management of HCV	214
Diagnostic approaches to HCV	214
Recommended treatment protocols for HCV	214
Interferon therapy for HCV.....	215
Limitations of current HCV therapies	215
Novel approaches to HCV.....	216
HCV protease inhibitors	216
<i>ABT-450</i>	217
<i>Boceprevir</i>	217
<i>Combined daclatasvir and asunaprevir.....</i>	217
<i>Faldaprevir.....</i>	217
<i>Glecaprevir/pibrentasvir combination</i>	218
<i>Narlaprevir.....</i>	218
<i>Sofosbuvir</i>	218
<i>Simeprevir</i>	218
<i>Small molecule HCV protease inhibitors</i>	219
<i>Telaprevir</i>	219
Innovations in interferon therapy for HCV	220
<i>AlbIFN-α2b.....</i>	220
<i>Directed evolution of gene-shuffled IFN-α for treatment of HCV</i>	220
<i>GEA007.1</i>	220
<i>Omega DUROS</i>	221
<i>PEG-IFN-λ.....</i>	221
<i>Personalizing interferon therapy of HCV.....</i>	221
Innovative ribavirin-based treatments	222

<i>Targeted delivery of hemoglobin-ribavirin conjugate for HCV.....</i>	222
<i>Taribavirin</i>	222
Nucleoside polymerase inhibitor.....	222
<i>Deleobuvir</i>	222
<i>Valopicitabine.....</i>	223
Host cell targets for hepatitis C therapy	223
<i>SP-10.....</i>	224
NS5a inhibitors.....	224
<i>Ledipasvir</i>	224
NS5b inhibitors.....	224
Novel combination of a protease inhibitor and a NS5a inhibitor.....	225
<i>Zepatier™</i>	225
Compounds targeting HCV receptor E2	225
Cyclophilin inhibitors	225
<i>Alisporivir</i>	225
Methylene blue	226
Naringenin	226
Nitazoxanide	227
Cyclosporine and analogs as anti-HCV agents.....	227
Clemizole and HCV.....	228
RNAi-based approaches to HCV	228
<i>Use of adenoviral vectors for RNAi</i>	228
<i>siRNAs for HCV</i>	229
<i>Limitations and drawbacks of siRNA therapy for HCV.....</i>	229
<i>Role of miRNA in viral infections</i>	230
<i>miR-122 antagonists</i>	230
Gene therapy for HCV.....	230
Vaccines for HCV	231
<i>HCV vaccine based on viral vectors to boost T cell memory</i>	231
<i>Vaccine based on neutralizing antibodies to HCV.....</i>	231
Clinical trials of HCV therapeutics.....	231
Limitations to the development of effective anti-HCV therapeutics	232
<i>Causes of treatment failure in chronic hepatitis C</i>	232
<i>HCV drug resistance.....</i>	233
Personalized management of HCV infection.....	233
Role of sequencing in personalized management of HCV	234
Concluding remarks about HCV therapy.....	235
Drug combinations for HCV	235
IFN-free combinations for HCV	235
Search for new drugs for HCV.....	236
Future needs in HCV therapy	236
10. Miscellaneous Commercially Important Virus Infections	238
Introduction	238
Herpes viruses	238
Neuroinvasive herpesviruses	238
Herpes simplex virus	238
Treatment of HSV-1	238
<i>Acyclovir.....</i>	238
<i>Vaccines for HSV.....</i>	239
<i>Antisense therapy for HSV-1</i>	239
Herpes simplex virus 2 and genital herpes	240
<i>Famciclovir.....</i>	240
<i>Pritelivir.....</i>	240
<i>Intravaginal microbicidal agents for HSV-2.....</i>	240
<i>Vaccines for HSV-2</i>	241
Herpes simplex keratitis	241
Herpes simplex encephalitis	242
Limitations of current HSV therapies	242
<i>Genomic diversity of HSV-1 as a cause of failure of vaccines</i>	242
<i>Recombinations in HSV-1 and HSV-2.....</i>	243
Herpes zoster virus	243
<i>Herpes zoster and chicken pox</i>	243
<i>Epidemiology of herpes zoster</i>	243
<i>Treatment of herpes zoster</i>	244
<i>Herpes zoster vaccines</i>	244
Epstein-Barr virus	245
Latent herpes virus infection	245
Cytomegalovirus	245
Current treatment of CMV	246
<i>Brincidofovir (CMX001).....</i>	246

<i>Valganciclovir hydrochloride</i>	246
<i>Limitations of current treatment and future</i>	246
Letermovir	247
T cell therapy for CMV	247
Vaccines for CMV	248
Gene therapy of CMV	248
Antisense approach to CMV	249
siRNA treatment of CMV	249
Human papilloma virus	249
Epidemiology.....	249
Vaccines for HPV.....	250
<i>Gardasil</i>	250
<i>Cervarix</i>	251
<i>DNA vaccine VGX-3100</i>	251
<i>GTL001 and GTL002</i>	251
<i>Vaccine based on fusion proteins of HPV envelope</i>	252
<i>Safety and limitations of HPV vaccines</i>	252
Antivirals for HPV.....	252
<i>Imiquimod</i>	252
Novel approaches against HPV.....	253
<i>Intrabody strategies for the treatment of HPV</i>	253
<i>A novel peptide to inhibit HPV</i>	253
<i>Heat shock protein-based antivirals</i>	253
Respiratory syncytial virus	254
Epidemiology.....	254
Current management of RSV	254
<i>Palivizumab</i>	254
<i>MDT-637</i>	255
<i>GS-5806</i>	255
<i>RNAi approach to RSV</i>	255
<i>Other approaches to RSV antivirals</i>	256
Vaccines for RSV.....	256
<i>BCG as a vaccine against RSV</i>	256
<i>Oral DNA vaccine for RSV</i>	256
<i>Neutralizing antibodies against preactive form of hRSV_F protein</i>	257
Challenges for development of RSV antivirals	257
Other respiratory viruses	257
Parainfluenzavirus type 3	257
Human metapneumovirus	257
Gastrointestinal viruses	258
Noroviruses.....	258
<i>Potential for development of antiviral agents against noroviruses</i>	259
<i>Vaccines against noroviruses</i>	259
<i>Precautionary measures during a novovirus outbreak</i>	260
Concluding remarks	260
11. Viruses with High Impact but Low Commercial Significance	262
Introduction	262
Chikungunya fever	262
Chikungunya antiviral therapy	263
Chikungunya vaccines	263
Enteroviruses	263
Enterovirus 71	263
Coxsackie virus.....	264
Japanese encephalitis	264
Vaccines for JE	264
Parvovirus	265
Polyomavirus JC	265
Rabies	266
Rabies vaccines	266
<i>Recombinant viral vaccines for rabies</i>	267
DNA vaccine against rabies	267
Rabies immune globulin.....	267
Monoclonal antibodies for rabies	267
NanoViricides approach for rabies	268
Protein-protein interactions as targets for antirabies drug discovery	268
siRNA-based approach against rabies	268
The Milwaukee protocol for rabies	269
Rotavirus	269
Epidemiology.....	269
Rotavirus genome	269

Vaccines against rotavirus.....	270
Viral hemorrhagic fevers	271
Bas-Congo virus associated with acute hemorrhagic fever.....	272
Crimean-Congo hemorrhagic fever.....	272
Dengue.....	273
<i>Epidemiology</i>	273
<i>Antivirals in development against dengue</i>	274
<i>Dengue vaccines</i>	275
<i>Dengvaxia</i>	276
<i>Elimination of dengue vector mosquitoes by fungus</i>	277
<i>Genetic elimination of dengue vector mosquitoes</i>	278
Ebola virus.....	278
<i>Pathogenesis and diagnosis of Ebola virus</i>	279
<i>Sequencing of the Ebola genome</i>	279
<i>Antiviral approaches to Ebola virus infection</i>	280
<i>Antivirals for Ebola based on inhibition of RNA polymerase</i>	280
<i>Cell entry blockers as antivirals for filoviruses</i>	281
<i>Development of RNAi-based antiviral drugs for Ebola</i>	281
<i>EbolaCide</i>	282
<i>Monoclonal antibody immunotherapy for Ebola</i>	282
<i>Vaccines for Ebola</i>	283
<i>Ebola whole virus vaccines</i>	285
<i>Companies developing antivirals against Ebola</i>	286
<i>Concluding remarks and future</i>	286
Human hanta viruses	287
Lassa fever	288
Marburg hemorrhagic fever	288
<i>Therapies in development against Marburg virus</i>	288
Yellow fever	289
<i>Vaccines for yellow fever</i>	289
<i>Sequencing of Aedes aegypti genome and control of yellow fever</i>	290
West Nile virus	290
Epidemiology.....	290
Pathogenesis	290
Treatment of West Nile neuroinvasive disease	291
Vaccines against WNV	291
Innovative treatments for WNV.....	291
Zika virus.....	292
Introduction to Zika virus.....	292
ZIKV in the USA.....	292
Clinical features of ZIKV	293
Molecular epidemiology of ZIKV	293
Molecular diagnosis of ZIKV infection.....	293
Neurological complications of ZIKV infection.....	293
<i>Pathomechanism of neurological complications of Zika</i>	294
<i>Microcephaly</i>	294
<i>Guillain-Barré syndrome</i>	295
Prevention and treatment of ZIKV infection	295
<i>Antiviral agents against ZIKV</i>	295
<i>Preventive measures against ZIKV infection</i>	296
<i>Vaccines for ZIKV</i>	296
<i>WHO views on challenges in management of ZIKV</i>	298
Western equine encephalitis.....	299
Tick-borne encephalitis.....	299
TBE vaccines	299
Zoonotic viral infections	299
Risk of spillover of new zoonotic viruses to humans.....	300
Vaccines for zoonotic viral diseases	300
Measles.....	301
Nipah virus	301
Virus bioterrorism and biowarfare.....	302
Smallpox as a biological weapon	302
Status of smallpox vaccination.....	302
<i>Dryvax vaccine</i>	302
<i>Modified Vaccinia Ankara (MVA)</i>	303
Strategies against virus bioterrorism and biowarfare	303
<i>Increasing resistance by stimulating innate immune mechanisms</i>	303
<i>Nanoviricides for combating viral bioterrorism</i>	303
Concluding remarks	304
12. Human coronaviruses	306

Introduction	306
SARS.....	306
Therapeutic approaches to SARS	306
MAbs for SARS	307
siRNA treatment of SARS	307
Middle East respiratory syndrome coronavirus	308
Development of therapeutics for MERS-CoV	309
MERS vaccines	309
Future directions for management of MERS	310
Coronavirus China 2019.....	310
Introduction and epidemiology	310
Genomics of coronaviruses.....	311
Genetic susceptibility for severity of COVID-19	311
Risk factors that increase morbidity and mortality in COVID-19	312
Molecular diagnosis of COVID-19	312
Serological assay for detection of SARS-CoV-2 antibodies	314
Reassessment of molecular diagnostics for COVID-19.....	314
<i>Point-of-care tests for COVID-19.....</i>	315
Pathogenesis of COVID-19	315
<i>Pathogenesis of pulmonary complications</i>	315
<i>Pathogenesis of neurological complications.....</i>	316
Strategies for developing therapies for COVID-19	316
Antivirals for COVID-19	317
<i>Clinical trials of COVID-19 therapies.....</i>	321
<i>Dexamethasone.....</i>	321
<i>Hydroxychloroquine</i>	321
<i>Favipiravir.....</i>	322
<i>Molnupiravir</i>	322
<i>Remdesivir.....</i>	323
<i>Monoclonal antibodies for COVID-19.....</i>	323
<i>Nanobodies for COVID-19</i>	323
Management of cytokine release syndrome in COVID-19	324
<i>Role of IL-6 in CRS.....</i>	324
<i>Tocilizumab.....</i>	324
<i>Edaravone.....</i>	325
Management of hypoxia in COVID-19	325
<i>Hyperbaric oxygen in COVID-19</i>	325
Discovery and development of new therapies for COVID-19	326
<i>Cell therapy for COVID-19.....</i>	326
<i>Exosomes derived from bone marrow mesenchymal stem cells.....</i>	326
<i>Gene editing with for COVID-19 by RNA-targeting CRISPR systems.....</i>	327
<i>Nanosponges for COVID-19.....</i>	328
<i>Role of vitamin D sufficiency in reducing COVID-19 mortality</i>	328
Immunotherapies for COVID-19.....	328
<i>Antibodies from patients as immune therapy for COVID-19</i>	328
<i>Monoclonal antibodies for COVID-19.....</i>	329
<i>Monoclonal antibodies and future vaccines</i>	329
Vaccines for COVID-19	329
<i>mRNA vaccines for COVID-19</i>	332
<i>Adenoviral vectors carrying gene for COVID-19 spike protein</i>	333
<i>Age-related reduction in immunity by vaccine against SARS-CoV-2</i>	334
<i>Comparison of vaccines for COVID-19</i>	334
<i>Operation Warp Speed.....</i>	335
<i>Oral COVID-19 vaccine.....</i>	335
<i>DNA vaccine for COVID-19.....</i>	336
<i>Other vaccines for COVID-19.....</i>	336
<i>Pitfalls in developing vaccines for COVID-19.....</i>	337
<i>Personalized vaccines for COVID-19</i>	337
<i>Personalized approach to passive antibody therapy for COVID-19</i>	337
<i>Protection from re-infection after COVID-19 as well as by vaccination</i>	338
<i>Protection against COVID-19 variants.....</i>	338
<i>Regulatory approval of COVID-19 vaccines.....</i>	339
<i>Safety of vaccination in pregnancy and during lactation</i>	339
Future of tackling with coronaviruses.....	341
<i>New antiviral targets</i>	341
<i>Repurposing drugs for COVID-19</i>	341
<i>Inhibiting complement hyper-activation in the lungs.....</i>	342
<i>Improving ability to respond to future coronavirus outbreaks</i>	342

Tables

Table 1-1: A practical classification of viruses.....	21
Table 1-2: Viruses causing encephalitis	30
Table 1-3: Vaccines vs therapeutics for viral diseases.....	33
Table 1-4: Historical landmarks in the development of antiviral therapies	33
Table 2-1: Classification of antiviral strategies.....	36
Table 2-2: Viral vs cellular targets for discovery of antivirals	37
Table 2-3: Viruses amenable to antisense oligonucleotides	51
Table 2-4: Inhibition of viral replication by RNAi	53
Table 3-1: Types of vaccines for viral diseases	61
Table 4-1: Role of nanobiotechnology in virology	72
Table 5-1: Methods of delivery of antiviral agents	80
Table 5-2: Role of nanotechnology for improving delivery of antivirals.....	87
Table 5-3: Commercially available liposomal antiviral vaccines	90
Table 6-1: SWOT of monoclonal antibodies	94
Table 6-2: SWOT of agents that prevent viral entry into cells	95
Table 6-3: SWOT of drugs interfering with intracellular replication	95
Table 6-4: SWOT of protease inhibitors	95
Table 6-5: SWOT of integrase inhibitors	95
Table 6-6: SWOT of maturation inhibitors	95
Table 6-7: SWOT of neuraminidase inhibitors	96
Table 6-8: SWOT of targeting Toll-like receptors (TLRs).....	96
Table 6-9: SWOT of topical antivirals agents against viral infections.....	96
Table 6-10: SWOT of gene therapy, antisense oligonucleotides, RNAi	96
Table 6-11: SWOT of vaccines	96
Table 6-12: SWOT of NanoViricides.....	97
Table 7-1: Anti-influenza approaches	105
Table 7-2: Antiviral drugs used for influenza	105
Table 7-3: Various approaches to production of influenza vaccines.....	120
Table 8-1: Drugs in clinical development for HIV/AIDS	155
Table 8-2: Strategies for gene therapy of AIDS	175
Table 8-3: Classification of HIV/AIDS vaccines in clinical trials.....	179
Table 8-4: Companies involved in developing gene therapy for HIV/AIDS	195
Table 9-1: Innovations in the treatment of HBV.....	208
Table 9-2: Recommended regimens for management of chronic HCV	214
Table 9-3: Innovations for management of HCV	216
Table 9-4: Antiviral agents for HCV targeting host cells	223
Table 9-5: HCV drugs in clinical trials	232
Table 10-1: Methods of delivery of acyclovir.....	239
Table 11-1: Antiviral strategies against Ebola virus infection	280
Table 11-2: Companies developing antiviral products against Ebola	286
Table 11-3: ZIKA vaccines in development.....	297
Table 11-4: Strategies against virus bioterrorism and biowarfare	303
Table 12-1: Drugs in development for COVID-19	317
Table 12-2: Clinical trials of hyperbaric oxygen in COVID-19 patients.....	325
Table 12-3: Vaccines in development for COVID-19	329

Figures

Figure 1-1: Endogenous retrovirus-disease link	23
Figure 1-2: Varieties of host and cell responses to viral infections.....	24
Figure 1-3: Cycle of infection and replication of a retrovirus	27
Figure 1-4: Viral-induced cancer.....	29
Figure 2-1: Pathogen sequencing as guide to personalized management viral infections	57
Figure 2-2: An integrated approach to viral diseases	57
Figure 2-3: Safe-in-man broad-spectrum antiviral agents	59
Figure 3-1: Mechanisms of immune activation by virally vectored vaccines	66
Figure 4-1: Schematic representation of NanoViricide attacking a virus particle	77
Figure 7-1: Evolution of mutations associated with virulence/drug resistance in H5N1	102
Figure 7-2: Mechanism of development of resistance to oseltamivir	108
Figure 8-1: Mode of action of some current anti-HIV drugs	146
Figure 8-2: Nanocarrier-mediated siRNA delivery for treatment of HIV/AIDS	193
Figure 9-1: Steps of HBV replication and site of action of various drugs	205
Figure 9-2: Omega DUROS device for interferon delivery in chronic hepatitis C	221
Figure 11-1: Strategies for development of ZIKV vaccines	297